Company intelligence / Profile preview

MDNA Life Sciences

West Palm Beach, Florida, United States

Ownership: Private
Employees: ~16
Development stage: Other

Overview

The Mitomic Prostate Test demonstrates very high diagnostic accuracy for clinically significant prostate cancer, cited as providing 100% Negative Predictive Value (no false negatives for significant cancer) in blood-based screening; clinical details for other tests under development not specified

Therapeutic areas: OncologyWomen's Health
Modalities: Device (diagnostic)Molecular diagnostic testLiquid biopsy
Industry: Molecular Diagnostics

Partnerships

Aspire Pharma Ltd. (UK distribution)Orion Diagnostica Oy (exclusive European distributor for MPT)

Beyond the preview

Go deeper on MDNA Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDNA Life Sciences.

Explore the full profile